SMT202400145T1 - Intermedi per la preparazione di inibitori c-terminali di hsp90 - Google Patents
Intermedi per la preparazione di inibitori c-terminali di hsp90Info
- Publication number
- SMT202400145T1 SMT202400145T1 SM20240145T SMT202400145T SMT202400145T1 SM T202400145 T1 SMT202400145 T1 SM T202400145T1 SM 20240145 T SM20240145 T SM 20240145T SM T202400145 T SMT202400145 T SM T202400145T SM T202400145 T1 SMT202400145 T1 SM T202400145T1
- Authority
- SM
- San Marino
- Prior art keywords
- intermediates
- preparation
- hsp90 inhibitors
- terminal hsp90
- terminal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261597004P | 2012-02-09 | 2012-02-09 | |
EP19193576.6A EP3656758B1 (en) | 2012-02-09 | 2013-02-08 | Intermediates for the preparation of c-terminal hsp90 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT202400145T1 true SMT202400145T1 (it) | 2024-05-14 |
Family
ID=47754998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM20240145T SMT202400145T1 (it) | 2012-02-09 | 2013-02-08 | Intermedi per la preparazione di inibitori c-terminali di hsp90 |
SM20190660T SMT201900660T1 (it) | 2012-02-09 | 2013-02-08 | Inibitori c-terminali di hsp90 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM20190660T SMT201900660T1 (it) | 2012-02-09 | 2013-02-08 | Inibitori c-terminali di hsp90 |
Country Status (25)
Country | Link |
---|---|
US (7) | US9422320B2 (it) |
EP (3) | EP2812341B1 (it) |
JP (1) | JP6121450B2 (it) |
KR (1) | KR102124109B1 (it) |
CN (2) | CN107474085B (it) |
AU (1) | AU2013216858C1 (it) |
BR (1) | BR112014019704B1 (it) |
CA (1) | CA2866814C (it) |
CY (1) | CY1122358T1 (it) |
DK (2) | DK2812341T3 (it) |
EA (1) | EA027147B1 (it) |
ES (2) | ES2974721T3 (it) |
FI (1) | FI3656758T3 (it) |
HK (2) | HK1205131A1 (it) |
HR (2) | HRP20240514T1 (it) |
HU (2) | HUE046939T2 (it) |
LT (2) | LT3656758T (it) |
MX (1) | MX361233B (it) |
NZ (1) | NZ629778A (it) |
PL (2) | PL2812341T3 (it) |
PT (2) | PT2812341T (it) |
RS (2) | RS65412B1 (it) |
SI (2) | SI2812341T1 (it) |
SM (2) | SMT202400145T1 (it) |
WO (1) | WO2013119985A1 (it) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SMT202400145T1 (it) | 2012-02-09 | 2024-05-14 | Univ Kansas | Intermedi per la preparazione di inibitori c-terminali di hsp90 |
EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
CA2952029A1 (en) * | 2014-06-24 | 2015-12-30 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
WO2016145219A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Treatment of peripheral neuropathies |
JP7402800B2 (ja) * | 2017-12-20 | 2023-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヘテロ芳香族化合物 |
IL315865A (en) | 2018-02-07 | 2024-11-01 | Reata Pharmaceuticals Inc | Co-crystal forms of a novobiocin analog and proline |
EA202092727A1 (ru) * | 2018-05-14 | 2021-04-20 | Рита Фармасьютикалз, Инк. | Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока |
WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2585091C (en) * | 2004-11-03 | 2016-07-19 | University Of Kansas | Novobiocin analogues as anticancer agents |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
WO2007095586A2 (en) * | 2006-02-14 | 2007-08-23 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US8044041B2 (en) | 2006-11-15 | 2011-10-25 | Forest Laboratories Holdings Limited | Phthalazine derivatives as inhibitors of protein kinase |
AU2008229216B2 (en) | 2007-03-20 | 2013-03-21 | Curis, Inc. | Fused amino pyridine as HSP90 inhibitors |
US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
JP5766617B2 (ja) * | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
JPWO2012008435A1 (ja) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
EA024647B1 (ru) | 2011-04-05 | 2016-10-31 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | ИНГИБИТОРЫ Hsp90 |
WO2012162054A1 (en) | 2011-05-20 | 2012-11-29 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
SMT202400145T1 (it) | 2012-02-09 | 2024-05-14 | Univ Kansas | Intermedi per la preparazione di inibitori c-terminali di hsp90 |
EP3066072B1 (en) | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
AU2014346368B2 (en) | 2013-11-11 | 2019-03-14 | The University Of Kansas | Coumarin based Hsp90 inhibitors with urea and ether substituents |
EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
CA2952029A1 (en) | 2014-06-24 | 2015-12-30 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
EA202092727A1 (ru) | 2018-05-14 | 2021-04-20 | Рита Фармасьютикалз, Инк. | Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока |
-
2013
- 2013-02-08 SM SM20240145T patent/SMT202400145T1/it unknown
- 2013-02-08 DK DK13706822T patent/DK2812341T3/da active
- 2013-02-08 BR BR112014019704-0A patent/BR112014019704B1/pt active IP Right Grant
- 2013-02-08 PT PT137068227T patent/PT2812341T/pt unknown
- 2013-02-08 HU HUE13706822A patent/HUE046939T2/hu unknown
- 2013-02-08 CA CA2866814A patent/CA2866814C/en active Active
- 2013-02-08 EP EP13706822.7A patent/EP2812341B1/en active Active
- 2013-02-08 HR HRP20240514TT patent/HRP20240514T1/hr unknown
- 2013-02-08 SM SM20190660T patent/SMT201900660T1/it unknown
- 2013-02-08 LT LTEP19193576.6T patent/LT3656758T/lt unknown
- 2013-02-08 LT LT13706822T patent/LT2812341T/lt unknown
- 2013-02-08 HU HUE19193576A patent/HUE066259T2/hu unknown
- 2013-02-08 US US14/377,616 patent/US9422320B2/en active Active
- 2013-02-08 ES ES19193576T patent/ES2974721T3/es active Active
- 2013-02-08 SI SI201331622T patent/SI2812341T1/sl unknown
- 2013-02-08 ES ES13706822T patent/ES2755093T3/es active Active
- 2013-02-08 PT PT191935766T patent/PT3656758T/pt unknown
- 2013-02-08 JP JP2014556739A patent/JP6121450B2/ja active Active
- 2013-02-08 RS RS20240452A patent/RS65412B1/sr unknown
- 2013-02-08 EP EP24161059.1A patent/EP4403552A3/en active Pending
- 2013-02-08 DK DK19193576.6T patent/DK3656758T3/da active
- 2013-02-08 CN CN201710729038.6A patent/CN107474085B/zh active Active
- 2013-02-08 NZ NZ629778A patent/NZ629778A/en unknown
- 2013-02-08 AU AU2013216858A patent/AU2013216858C1/en active Active
- 2013-02-08 KR KR1020147025348A patent/KR102124109B1/ko active Active
- 2013-02-08 CN CN201380019057.XA patent/CN104271587B/zh active Active
- 2013-02-08 PL PL13706822T patent/PL2812341T3/pl unknown
- 2013-02-08 WO PCT/US2013/025387 patent/WO2013119985A1/en active Application Filing
- 2013-02-08 SI SI201332079T patent/SI3656758T1/sl unknown
- 2013-02-08 FI FIEP19193576.6T patent/FI3656758T3/fi active
- 2013-02-08 RS RS20191454A patent/RS59719B1/sr unknown
- 2013-02-08 MX MX2014009608A patent/MX361233B/es active IP Right Grant
- 2013-02-08 PL PL19193576.6T patent/PL3656758T3/pl unknown
- 2013-02-08 EP EP19193576.6A patent/EP3656758B1/en active Active
- 2013-02-08 EA EA201491496A patent/EA027147B1/ru unknown
-
2015
- 2015-06-19 HK HK15105894.9A patent/HK1205131A1/xx unknown
-
2016
- 2016-08-03 US US15/227,230 patent/US10030041B2/en active Active
-
2018
- 2018-06-12 HK HK18107629.4A patent/HK1249519A1/zh unknown
- 2018-06-26 US US16/018,401 patent/US10590157B2/en active Active
-
2019
- 2019-10-24 HR HRP20191940TT patent/HRP20191940T1/hr unknown
- 2019-11-11 CY CY20191101180T patent/CY1122358T1/el unknown
-
2020
- 2020-02-05 US US16/783,025 patent/US10882881B2/en active Active
- 2020-12-04 US US17/112,060 patent/US11390640B2/en active Active
-
2022
- 2022-07-12 US US17/863,135 patent/US12024536B2/en active Active
-
2024
- 2024-05-17 US US18/667,496 patent/US20240417419A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243175A1 (zh) | 標記的hsp90抑製劑的用途 | |
HK1206023A1 (en) | Inhibitors of the fibroblast growth factor receptor | |
HK1207382A1 (en) | Methods for the synthesis of ethylfumarates and their use as intermediates | |
ZA201305972B (en) | Method for the preparation of biphephos | |
SMT202400145T1 (it) | Intermedi per la preparazione di inibitori c-terminali di hsp90 | |
ZA201207397B (en) | Process for the preparation of dexlansoprazole | |
EP2596007A4 (en) | PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS | |
ZA201405824B (en) | Process for the preparation of substituted phenylpropanones | |
ZA201300546B (en) | Process for the preparation of 3-haloalkylpyrazoles | |
PT2390246T (pt) | Processo para a preparação de aminaftona | |
PL391551A1 (pl) | Sposób otrzymywania bakteriofagów | |
ZA201209495B (en) | Novel methods for the preparation of p2x7r antagonists | |
PL2598504T3 (pl) | Sposób otrzymywania dimiracetamu | |
GB201007519D0 (en) | Means for inhibiting the expression of rragb | |
IL224304A (en) | A process for making dichlorobulben |